

Leptin inhibits insulin-stimulated incorporation of glucose into lipids and stimulates glucose decarboxylation in isolated rat adipocytes

RB Ceddia¹, WN William Jr², FB Lima² and Curi R²

¹Department of Physical Education - Fluminense Federal University, UFF, Rio de Janeiro - Brazil, ²Department of Physiology and Biophysics, Av. Prof. Lineu Prestes, 1524, University of São Paulo, USP, 05508 900 - Brazil.

(Requests for offprints should be addressed to R Curi)

Abstract

Leptin is an adipocyte hormone involved in the regulation of energy homeostasis. Generally accepted biological effects of leptin are inhibition of food intake and stimulation of metabolic rate in *ob/ob* mice, that are defective in the leptin gene. In contrast to these centrally mediated effects of leptin, we are reporting here on leptin effects on glucose incorporation into lipids and glucose decarboxylation in adipocytes isolated from male lean albino rats. Adipocytes previously cultivated (15 h) in the presence of leptin presented a 25 % ($P < 0.05$) reduction of the insulin stimulated incorporation of glucose into lipids. Concurrently, the basal conversion of (U-¹⁴C)D-glucose into ¹⁴CO₂ increased (110 %

in the leptin cultivated adipocytes and reached values (1.54 nmol/10⁵ cells) similar to the insulin stimulated group (not cultivated with leptin) (1.40 nmol/10⁵ cells). In addition, in the presence of insulin, the leptin cultivated adipocytes elicited a 162 % ($P < 0.05$) increase in ¹⁴CO₂ production that was significantly higher than the increase observed for the not-leptin-cultivated insulin group (92%). We conclude that leptin: 1) directly inhibits the insulin stimulated glucose incorporation into lipids; 2) stimulates glucose decarboxylation, and also potentiates the effect of insulin on glucose decarboxylation in isolated adipocytes. Leptin *per se* does not alter glucose incorporation into lipids.

Introduction

The *ob* gene product, leptin, is produced in adipose tissue. In *ob/ob* mice, a mutation in the *ob* gene prevents normal leptin production and results in obesity and diabetes. Daily injections of recombinant leptin inhibit food intake and reduce body weight and fat mass in *ob/ob* mice (Campfield *et al.* 1995, Halaas *et al.* 1995), and normalize glycemia (Halaas *et al.* 1995, Pelleymounter *et al.* 1995). It has also been observed that changes in glycemia precede changes in body weight (Pelleymounter *et al.* 1995). Additionally, pair-feeding studies (Levin *et al.* 1996) and experimental hyperleptinemic animal models (Unger 1997) provide compelling evidence that leptin exerts adipose-reducing effects in excess of those induced by decreases in food intake, suggesting a significant metabolic regulation role for leptin, in addition to appetite suppression. It has been recently reported that leptin stimulates glucose transport and glycogen synthesis in C₂C₁₂ myotubes (Berti *et al.* 1997) in opposition to previous findings that leptin impairs insulin signaling, i.e. insulin receptor autophosphorylation and insulin-receptor substrate (IRS)-1 phosphorylation in rat-1 fibroblasts, NIH3T3 cells (Kroder *et al.* 1996) and HepG2 cells (Cohen *et al.* 1996).

Since the identification of the Ob protein receptor in adipocytes (Hoggard *et al.* 1997), it has been speculated that leptin may also exert an autocrine effect. However, very few data are available regarding this issue. Recently, it was demonstrated that in isolated rat adipocytes leptin *per se* increases glucose uptake in adipocytes but impairs the

metabolic effects of insulin (Müller *et al.* 1997). According to Walder *et al.* (1997) the binding of insulin to its receptors is inhibited by leptin. In order to test whether leptin is able to directly alter glucose metabolism in adipocytes, (U-¹⁴C)D-glucose incorporation into lipids and the conversion of (U-¹⁴C)D-glucose into ¹⁴CO₂ were measured in incubated rat adipocytes. The effect of leptin on glucose metabolism was evaluated either in the presence or absence of insulin.

Materials and Methods

Experimental animals

Male albino rats (Wistar strain), weighing 140-160 g were maintained on a 12-12 h light-dark cycle at 22 °C and fed (*ad libitum*) a standard laboratory chow. Ethics approval was granted for these studies by the Institute of Biomedical Sciences, Animal Experimental Committee, University of São Paulo.

Primary culture of adipocytes and washing procedures

Adipocytes were isolated as previously described (Lima & Garvey 1991). Briefly, rats were killed by cervical dislocation, and epididymal fat pads removed under sterile conditions. Isolated cells were obtained by shaking (150 orbitals/min) finely minced tissue (2-4g) in 4-oz. sterile polypropylene containers at 37° C for 45 min in Dulbecco's MEM (10 ml) containing 25 mM Hepes, collagenase (1mg/ml), and albumin (40 mg/ml). Cells were then washed in Dulbecco's MEM

containing 20 mM Hepes, 2% fetal calf serum, and 1% bovine serum albumin, and filtered through nylon mesh. All Dullbecco's MEM buffers contained 5.6 mM D-glucose, and were added with penicillin (20 U/ml) and streptomycin (20 mg/ml). Adipocyte number was determined according to a previously described method (Lima & Garvey 1991). Isolated adipocytes (5×10^4 cells/ml) were then placed in air tight, 50 ml sterile polypropylene tubes with cells floating on top of the medium in a thin cell layer, and were maintained in primary culture at 37° C for 15 h either in the presence or absence of murine leptin (10 ng/ml) [Amgem Inc., Thousand Oaks, California, USA].

Incorporation of (U-¹⁴C)D-glucose into lipids and conversion of (U-¹⁴C)D-glucose into ¹⁴CO₂

Incorporation of (U-¹⁴C)D-glucose into lipids and the conversion of (U-¹⁴C)D-glucose into ¹⁴CO₂ were determined using the methods described by Lima *et al.* (1994) and Rodbell (1964). Briefly, the adipocytes were washed three times and resuspended to 5% lipocrit. One ml of the cell suspension was incubated for 1 h (37° C with shaking) in a 20-ml plastic scintillation flasks which had a centered-isolated well containing a loosely folded piece of filter paper moistened with 0.2 ml of 2-phenylethylamine/methanol (1:1, v/v). The incubation medium contained 0.2 μCi/ml of (U-¹⁴C)D-glucose, 5.6 mM of D-glucose in the presence or absence of insulin (10000 μU/ml). After the 1-hour incubation period the medium was acidified with 0.3 ml of H₂SO₄ (8 N) and the flasks incubated for a further 60 min period. At the end of the incubation, the filter paper was transferred into scintillation vials for measurement of radioactivity and the reaction mixture was treated with 5 ml Dole's reagent (isopropanol:n-heptane:H₂SO₄, 4:1:0.25, v/v/v) for lipid extraction (Dole & Meinertz 1960).

Statistical analysis

All data are expressed as the mean ± S.E.M. Statistical analysis was performed by one-way analysis of variance (ANOVA) with Tukey-Kramer multiple comparison test. The level of significance was set at $P < 0.05$.

Results and Discussion

Adipocytes cultivated (15 h) in the presence of 10 ng/ml of leptin did not elicit a significant alteration on basal (U-¹⁴C)D-glucose incorporation into lipids compared to control. However, when these adipocytes were stimulated by insulin, a significant reduction (25%) of the incorporation of (U-¹⁴C)D-glucose into lipids (Figure 1) was observed. Concurrently, the basal conversion of (U-¹⁴C)D-glucose into ¹⁴CO₂ increased (110%) in the leptin cultivated adipocytes and reached values (1.54 nmol/10⁵ cells) similar to the insulin stimulated group (not cultivated with leptin) (1.40 nmol/10⁵ cells). In addition, the leptin cultivated adipocytes when in the presence of insulin




Figure 1 Incorporation of (U-¹⁴C)D-glucose into lipids (nmol/10⁵ cells) in adipocytes cultivated (15h) in the presence and absence of leptin. Control = no insulin / no leptin; I10000 = Insulin stimulated (10000 μU/ml); Lep 10 = Leptin cultivated (10 ng/ml); L10 I10000 = Leptin cultivated (10 ng/ml) + Insulin stimulated (10000 μU/ml). ^a $P < 0.05$ vs control and Lep10; ^b $P < 0.05$ vs control, I10000 and Lep10; n = 14.

elicited an increase of 162% ($P < 0.05$) in ¹⁴CO₂ production, that was significantly higher than the increase observed for the insulin stimulated adipocytes [not cultivated with leptin] (92 %) [Figure 2].

A recent publication described that long-term cultivation of isolated adipocytes in the presence of leptin results in impairment of insulin action on metabolic processes including glucose transport, glycogen synthesis and lipogenesis (Müller *et al.* 1997).

According to our results, leptin seems to shift the adipocyte metabolism, reducing the synthesis of lipids from glucose, and increasing the oxidation rate of this metabolite that could otherwise be stored as fat in adipose tissue. These results are also consistent with recently *in vivo* published data from Sarmiento *et al.* (1997) and Zhou *et al.* (1997) who have reported that hyperleptinemia up-regulates UCP-2 expression in fat tissue (epididymal, retroperitoneal, and subcutaneous). In fact, the expression of UCP-2 was increased up to 2-fold in adipose tissue (white and brown) of leptin treated mice (Sarmiento *et al.* 1997), and the lipid content of the fat cells was dramatically reduced, reaching non detectable values. These *in vivo* studies provide evidence that leptin exerts a powerful adipose reducing effect, however they do not clarify if it is a result of a direct or a CNS-mediated effect of leptin. In the present study, we provide evidence that leptin is capable of directly interfering with adipocyte metabolism. In addition to isolated adipocytes (Walder *et al.* 1997, Müller *et al.* 1997), direct effects of leptin on glucose and lipid metabolism have also already been reported on C₂C₁₂ myotubes (Berti *et al.* 1997), and skeletal muscle (Muioio *et al.* 1997, Liu *et al.* 1997).




Figure 2 Incorporation of (U-¹⁴C)D-glucose into ¹⁴CO₂ (nmol/10⁵ cells) in adipocytes cultivated (15h) in the presence and absence of leptin. Control = no insulin / no leptin; I10000 = Insulin stimulated (10000 μU/ml); Lep 10 = Leptin cultivated (10 ng/ml); L10 I10000 = Leptin cultivated (10 ng/ml) and Insulin stimulated (10000 μU/ml). ^aP<0.05 vs control; ^bP<0.05 vs control and I10000; n = 14.

These findings indicate that, as a hormone, leptin may exert multiple effects in different peripheral tissues, independently of signaling to the CNS.

In non obese humans, plasma leptin values lie between 1 and 20 ng/ml (Bauman *et al.* 1996). The concentration of leptin applied in our experiments (10 ng/ml) is within the physiological range. It indicates that, at least in adipose tissue, it is not necessary supra-physiological concentrations to observe direct effects of leptin.

Taken as a whole, these data led us to suggest that leptin exerts an autocrine effect as an anti obesity hormone controlling the amount of energy stored in adipocytes (Ceddia *et al.* 1998). Further studies are necessary to clarify the relationship between obesity and reduced insulin sensitivity and the role of leptin in the development of NIDDM in obese subjects.

Acknowledgments

The authors are indebted to the technical assistance of J R. Mendonca, G de Souza and CK Miyasaka. We would like to

thank Amgem Inc., Thousand Oaks, California, for kindly supplying leptin. This study was supported by FAPESP, CNPq, CAPES and PRONEX (168/97).

References

- Bauman WA, Spungen AM, Zhong YG, Mobbs CV 1996 *Hormone and Metabolic Research* **28** 732-736.
- Berti L, Kellerer M, Capp E & Haring HU 1997 *Diabetologia* **40** 606-609.
- Campfield LA, Smith FJ, Guisez Y, Devos R & Burn P 1995 *Science* **269** 546-549.
- Ceddia RB, William Jr WN, Lima FB, Carpinelli AR & Curi R 1998 *Brazilian Journal of Medical and Biological Research* **31** 715-722.
- Cohen B, Novick D & Rubinstein M 1996 *Science* **274** 1185-1188.
- Dole VP & Meinertz H 1960. *Journal of Biological Chemistry* **235** 2595-2599.
- Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK & Friedmann JM 1995 *Science* **269** 543-546.
- Hoggard N, Mercer JG, Rayner DV, Moar K, Trayhurn P & Williams LM 1997 *Biochemical and Biophysical Research Communications* **232** 383-387.
- Kroder G, Kellerer M & Haring HU 1997. *Experimental and Clinical Endocrinology and Diabetes* **104** 66.
- Levin N, Nelson C, Gurney A, Vandlen R & De Sauvage F 1996 *Proceedings of the National Academy of Sciences of the USA* **93** 1726-1730.
- Lima FB, Bao S & Garvey WT 1994 *Diabetes* **43** 53-62.
- Liu YL, Emilsson V & Cawthorne MA *FEBS Lett* **411** 351-355.
- Muoio DM, Dohn GL, Fiedorek FT Jr, Tapscott EB & Coleman RA 1997 *Diabetes* **46** 1360-1363.
- Müller G, Ertl J, Gerl M & Preibish G 1997 *Journal of Biological Chemistry* **272** 10585-10593.
- Pelleymounter MA, Cullen MJ, Baker MB, Hecht R, Winter D, Boone T & Collins F 1995 *Science* **269** 540-543.
- Rodbell M 1964 *Journal of Biological Chemistry* **239** 375-380.
- Sarmiento U, Benson B, Kaufman S, Ross L, Qi M, Scully S & DiPalma C 1997 *Laboratory Investigation* **77** 243-256.
- Unger RH 1997 *Trends in Endocrinology and Metabolism* **8** 276-282.
- Walder K, Filippis A, Clark S, Zimmet P & Collier GR 1997 *Journal of Endocrinology* **155** R5-R7.
- Zhou YT, Shimabukuro M, Koyama K, Lee Y, Wang MY, Trieu F, Newgard CB & Unger RH 1997 *Proceedings of the National Academy of Sciences of the USA* **94** 6386-6390.